GlassScriptPhysician profile
Balveen Singh
NPI 1164753745
$222,047.66
in general payments reported to CMS, 2019-2025
31 companies · $66K in 2025
The $66K reported for 2025 was more than what 98% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,707 · 2020: $3,071 · 2021: $3,863 · 2022: $28K · 2023: $40K · 2024: $76K · 2025: $66K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $93K · Honoraria: $31K · Travel and Lodging: $26K · Consulting Fee: $16K · Food and Beverage: $14K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $3,200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $93,231.00 |
| Honoraria | $30,840.00 |
| Travel and Lodging | $25,686.31 |
| Consulting Fee | $16,000.00 |
| Food and Beverage | $13,721.36 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $3,200.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $143,508.48 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Axsome Therapeutics, INC. | $63,915.84 | 2023-2025 | Auvelity |
| Alkermes, INC. | $2,341.84 | 2019-2025 | Aristada, Lybalvi |
| Abbvie INC. | $2,114.78 | 2021-2025 | Vraylar |
| Neurocrine Biosciences, INC. | $1,828.39 | 2019-2025 | Ingrezza |
| Neuronetics, INC. | $1,745.34 | 2023-2024 | Neurostar Tms Therapy System |
| Janssen Pharmaceuticals, INC | $1,121.13 | 2019-2025 | Invega Sustenna, Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,066.26 | 2020-2025 | Caplyta |
| Sunovion Pharmaceuticals INC. | $1,041.31 | 2019-2022 | |
| Lundbeck LLC | $681.09 | 2019-2025 | Abilify Maintena, Rexulti |
| Corium, LLC | $546.16 | 2022-2024 | Azstarys |
| Allergan, INC. | $387.98 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $339.14 | 2024-2025 | Cobenfy |
| Indivior INC. | $209.20 | 2022-2024 | Perseris |
| Boston Scientific Corporation | $163.65 | 2024-2025 | General - Pain Management |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $161.51 | 2022 | |
| Jazz Pharmaceuticals INC. | $147.42 | 2021 | |
| Almatica Pharma LLC | $136.36 | 2024-2025 | Loreev Xr |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $107.68 | 2019-2025 | Rejoyn |
| Vanda Pharmaceuticals INC. | $79.30 | 2025 | Fanapt |
| Novo Nordisk INC | $71.67 | 2025 | Ozempic, Wegovy |
| Collegium Pharmaceutical, INC. | $60.54 | 2025 | Jornay Pm |
| Teva Pharmaceuticals USA, INC. | $52.23 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $47.77 | 2022-2023 | Trintellix |
| Orexo US, INC. | $44.28 | 2024 | Zubsolv |
| Bioxcel Therapeutics, INC. | $24.52 | 2023 | Igalmi |
| Avanir Pharmaceuticals, INC. | $22.14 | 2019 | |
| Pfizer INC. | $21.94 | 2023 | |
| Neos Therapeutics, LP | $20.91 | 2023 | Adzenys Xr-Odt |
| Luye Pharma (USA) LTD. | $20.76 | 2025 | Erzofri Extended-Release |
| Alfasigma USA, INC. | $18.04 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Balveen Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.